• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 27th July 2010

Part 2: 2010 Lecture on US Health Reform

Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care reform. This is the second of two posts that summarises his remarks. It reviews…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
garber1-7-15-10

Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care reform. This is the second of two posts that summarises his remarks. It reviews some of the key provision of the law, summarises the factors that will affect its impact, and considers whether US health care will improve as a result.

OHE annually sponsors a lecture that examines an important issue in health care. This year’s speaker was Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research at the School of Medicine.  His presentation, ‘US Healthcare Reform: Monumental Health System Transformation or Fatally Flawed Compromise?’, is summarised in two blog posts.  The second of these follows.

Objectives and key provisions of the Patient Protection and Affordable Care Act

A broad set of health care delivery and payment changes are to be put into effect.  ‘Health insurance exchanges’ are an important part of this.  These are state-level ‘marketplaces’ of health insurance plans, with a range of offerings; benefits and premiums will be transparent to the buyer. Plans, which will compete on cost and quality, will be subject to regulatory control to ensure availability and specify how rates are set.

Numerous programmes also are included in the legislation aimed at changing how doctors and hospitals are paid.  For example, some are intended to develop and implement changes in Medicare; others will focus on tying payment to outcomes.

An Independent Payment Advisory Board (IPAB) will debut in 2014 and have significant power over Medicare expenditures, among other things, if Medicare expenditures rise above the rate designated by the law.  The legislation provided for an unprecedented amount of independence from Congress, a major procedural change for Medicare.  However, the IPAB is subject to limits: it cannot recommend changes that would ‘ration’ care (not defined in the law), increase the collection of revenues to pay for Medicare, increase the out-of-pocket costs for Medicare recipients or restrict benefits.  Before 2019, most physician and hospital services are exempt from payment rate reductions by the IPAB, although Congress itself can pass legislation reducing payments.

Comparative effectiveness research will be the focus of the new Patient-Centered Outcomes Research Institute.  This body will not only perform literature reviews and undertake modelling efforts, but also collect new data of various kinds.  It is charged with looking at what works best for whom and under what circumstances as well as patterns of care and benefit design.  However, strict limits are placed on Institute powers: it cannot specify a cost-effectiveness threshold or make coverage decisions; it may only make recommendations.  In practice, according to Dr. Garber, commercial insurers and government payers both will use this information to make coverage decisions, bundle payments and take other steps to improve care and outcomes.

Will changes under the new law make US health care better — or worse?

It is easy to make an argument for either, according to Dr. Garber.

The situation could get worse. For example, implementation of some key insurance features depends on action by the states: each state must set up its own health insurance exchange, must establish a high-risk pool, and continue to administer and partially fund the joint federal-state Medicaid programme.  Dr Garber pointed out that not all States are enthusiastic and not all are well equipped to develop and implement such programmes.

Access to care could worsen for some populations.  Physicians, for example, could stop taking Medicare or Medicaid patients if large enough discrepancies develop between what they are paid by these government programmes and what commercial insurers pay.

Demonstration projects authorised under the law to develop new approaches at the hospital level could fail or be useful only in a subset of hospitals.

Individuals still may not purchase insurance because the subsidies are too low or those who do purchase care will be those most likely to need care – dramatically driving up costs for insurance plans.  According to Dr Garber, it’s already the riskiest who are most likely to purchase individual policies. Finally, the new financial penalties for many individuals who do not purchase insurance will be lower – often dramatically so – than the cost of insurance.

The legislation also may promote monopoly power among providers or insurers, which in turn can lead to high prices for commercial insurance.  This could lead to government attempts to regulate the premiums insurers charge, similar to what has happened in Massachusetts.

The situation could improve. For example, incentives for physicians and hospitals to integrate care better already are beginning to produce results, according to Dr Garber.  Payment incentives to improve health outcomes may work; as may emphasis on primary care and prevention.  Medical device makers may be encouraged to give greater emphasis to new technologies that provide better outcomes at lower costs.  And many of the fears about adverse effects of the legislation may not materialize.

What will determine the outcome?

Four factors were identified by Dr Garber as key.  First, how and how well the law is implemented is critical.  This will be a very complex set of tasks and depends heavily on effective leadership at the federal level.  ‘Rule making’, the development of regulations that implement the law, can be done poorly or well – and will have major impact.

The other three factors are changes in the behaviour of providers, employers and individuals, and Congress.  Changing the behaviour of providers is the target of much of the legislation.  It is providers that are at the centre of changes in delivery and organization of care and have tremendous responsibility for improving care.  Employers and individuals also are expected to contribute to health improvement and to help make the changes in insurance work well.  And, finally, what Congress does in the coming years will matter.  Although repeal is not likely, Congress could take actions – such as increasing payments to doctors under Medicare – that would compromise cost savings.  Dr Garber believes that budgetary concerns will make Congress more reluctant than in the past to agree to payment increases and other policies that increase expenditures.

Suppose the legislation had not passed?  The ‘status quo’ was not stable, Dr Garber pointed out – problems were worsening and increasing.  Without reform legislation, the prospects for reductions in costs and sustained improvements in health outcomes were unfavourable.  He believes this legislation is a step in the right direction.

The full text of Dr Garber’s lecture now is available as part of the OHE Annual Lecture series.

  • Healthcare Systems
  • Annual Lecture

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!